Erosive Esophagitis (EE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Erosive Esophagitis (EE) Market Outlook
Thelansis’s “Erosive Esophagitis (EE)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Erosive Esophagitis (EE) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Erosive
Esophagitis (EE) Overview
Erosive
esophagitis (EE) is a common symptom of gastroesophageal reflux disease (GERD)
(GERD). Without continued treatment, most patients with healed EE
(approximately 80% – 90%) will relapse within 6 – 12 months. The major
esophageal complications of EE include ulcer bleeding and strictures. Although
death from EE is uncommon, these complications are associated with significant
morbidity and mortality rates. Although there is some overlap in acid exposure
among esophagitis grades, the severity of EE is related to the duration of
esophageal acid exposure. Because of their ability to control esophageal acid
exposure, symptoms, and esophagitis, acid-suppressive therapy with proton pump
inhibitors (PPIs) is recommended as first-line therapy for GERD and EE. Esomeprazole
is the S-enantiomer of the racemic PPI omeprazole, with which it shares the
exact pharmacodynamic mechanism of action. Both of these PPIs block the proton
pump H+/K+ adenosine triphosphatase.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment